top of page

Nutra Pharma Announces Nyloxin Distribution Plans for Canada

May 14, 2015

Nutra Pharma Has Announced That They Have Engaged the Nature's Clinic to Begin the Process of Distributing Nyloxin(R) in Canada

CORAL SPRINGS, FL--(Marketwired - May 14, 2015) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin® for marketing and distribution in Canada.

"We recently announced our plans for distribution in India and China," stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "I'm excited to announce that we have begun working with Canadian distributors to register Nyloxin for sale throughout Canada," he continued. "We already have dedicated product users in Canada that have been purchasing Nyloxin for personal consumption. Regulatory approval will allow us to warehouse, market and distribute Nyloxin throughout the country and permit for the eventual retail sales of our brands in Canadian stores," he concluded.

According to Euromonitor, the OTC analgesics drug category in Canada was worth $788 million in 2014. Cira Medical Services, a market leader committed to helping Canadians live healthier lives, released a white paper this month titled "Chronic Pain: The Importance of a Multidisciplinary Approach to Diagnosis and Treatment". The paper reported that one in five adult Canadians suffer from chronic pain -- and more than 70% of these cases report suffering simultaneously from severe levels of depression. Stemming from these cases, the estimated cost of chronic pain in Canada in terms of health care and lost productivity is reported at between $50-60 billion annually.

"We are extremely pleased to be working with Nutra Pharma Corp.," commented Chris Sullivan, President of the Nature's Clinic. "We already have some incredible success stories from Canadians successfully using Nyloxin and Pet Pain-Away. I have used these products first-hand with fantastic results and can't wait to help them become a household name when it comes to pain," he continued. "We believe that we can get all of these products approved for re-sale in the Canadian market this calendar year. In preparation for these sales, we've already begun setting up our Chatham, Ontario warehouse facility for distribution and fulfillment," he concluded.

Chris Sullivan has been in the natural healthcare field for more than 23 years and is a respected herbalist and homeopathic practitioner.

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away.

For additional information about Nutra Pharma, visit: or

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The engagement of the Nature's Clinic should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
bottom of page